Zheqi Li

3 weeks ago | nature.com | Zheqi Li |Xintao Qiu |Marco Seehawer |Maeve McFadden |Eva Papachristou |Natalie Kingston | +17 more

AbstractBasal breast cancer is a subtype with a poor prognosis in need of more effective therapeutic approaches. Here we describe a unique role for the KDM4C histone lysine demethylase in KDM4C-amplified basal breast cancers, where KDM4C inhibition reshapes chromatin and transcriptomic landscapes without substantial alterations of its canonical substrates, trimethylated histone H3 lysine 9 (H3K9me3) and lysine 36 (H3K36me3).

Nov 20, 2024 | cell.com | Marco Seehawer |Zheqi Li |Triet M. Bui |Pierre Foidart |Jun Nishida |Clive S. D’Santos | +18 more

ResultsBoth KDM5A and KDM5B were reported to be amplified and overexpressed in breast cancer.7,14 However, paralog-specific differences between luminal and basal breast cancer have not been analyzed. Thus, we assessed the mutational landscape of KDM5 paralogs in luminal A (LumA) and basal breast tumors in the TCGA cohort.